We believe the three companies we are including as the 3 “Best Buys” in this issue offer the best shelter against a slowing economy, and the greatest opportunity for share-price appreciation regardless of what happens next. We recommend investors put these names at the top of their “buy” list.
Today, Porter says: If you’ve never shorted a stock before, start small… just sell one share short. It’s a good way to learn how to profit from companies that are definitely going to collapse in a credit-default cycle. Don’t just watch your savings evaporate. Do something. And do it now.
Asymmetric information is something you must avoid falling prey to as an investor. There are laws protecting individual investors, but there are still ways to get caught on the wrong side of a transaction.
Most people believe they must take risks and take on leverage and do all other kinds of financial wizardry because they’re not as smart as Warren Buffett. But that’s all nonsense. All you must do is buy the biggest and best businesses, in the best industries. That’s all. It’s obvious. And it’s easy.
Dear Biotech Frontiers subscribers, One of the most important qualities that separates professional investors from amateurs is the capacity to face reality when it becomes clear an investment thesis has broken down. As I’ve said before, hope is not a strategy. Unfortunately, that moment has come regarding our Biotech Frontiers investment in Iovance Biotherapeutics (Nasdaq:
EchoStar (Nasdaq: SATS) reported its results for the quarter ended March 31. The news pushed up our Hughes Satellite bonds to a price where we recommended selling. Operating profit for the Hughes Satellite business – the business that issued the 5.25% secured bonds maturing August 1, 2026, in the Distressed Investing portfolio – rose 8.1%
In the heart of America’s Corn Belt, the company whose bond we recommend in this issue has quietly transformed itself from a traditional ethanol producer into a biotech innovator – unlocking more from every kernel of corn than anyone thought possible.
Unlike in the first negative-EV biotech basket, editor Erez Kalir doesn’t anticipate having a Big Picture catalyst that causes our recommendations to rise in price. This time, the catalyst will come from the biotech sector itself: The advances emerging are as transformative as any in the history of biotech